ART Program of the HIV Vaccine Trials Network Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development HVTN Organization HVTN functions under a cooperative agreement with the US National Institutes of Health
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Margaret Wecker, PhD
Associate Director, Scientific Operations and Business Development
The HIV Vaccine Trials Network (HVTN), a collaboration of scientists from 28 research sites (figure), announced this year that participants who become infected during HVTN vaccine trials will receive long-term antiretroviral treatment.
Disburse funds to RPIC
Receive reports of fund disbursement and program termination
RPIC (The fiduciary)
Applies for funding
Report of fund disbursement
purchase of medication for given participant
Report termination of program
national plan status changeResponsibilities
As of September, 2007: 79 HIV-infected participants, out of a total of 5764 enrollees.